Redefining Treatment Success in Psoriasis

In "Redefining Treatment Success in Psoriasis," our panel delves into how treatment expectations for plaque psoriasis have evolved alongside more efficacious therapies, and how clinicians navigate decisions around modifying or switching treatment regimens.

The panel opens by framing the shift in treatment goals, noting that modern biologics can achieve complete clearance in roughly 60% of patients at one year, a dramatic improvement over what was available 15 years ago. The NPF treat-to-target guidelines are referenced, which recommend less than 1% BSA at three months ideally, less than 3% BSA at three months as an acceptable threshold, and less than 1% BSA at six months, acknowledging that some therapies require the full six months to reach their maximum effect.

The discussion also highlights that meeting these guidelines carries implications beyond skin clearance, pointing to emerging evidence suggesting that achieving near-complete clearance may reduce the risk of developing psoriatic arthritis and potentially other comorbidities as well.

The panelists emphasize that treatment goals are highly individualized, with some patients satisfied by partial improvement if their most visible or symptomatic areas are addressed, while others view anything short of 100% clearance as a failure. The NPF's newer definition of on-treatment remission is also discussed, setting an even higher bar of complete clearance maintained for at least six months, with the panel generally waiting 6 to 9 months before reassessing therapy for skin and up to 9 to 12 months for joints.

The panel concludes by agreeing that before switching therapies, optimizing topical options including newer non-steroidal agents is an important step, particularly for patients with small amounts of residual disease, in order to preserve future biologic options and avoid premature cycling through available therapies.

Our next episode, "Addressing Unmet Needs in Plaque Psoriasis," further explores psoriasis highlighting the remaining clinical challenges in achieving complete disease control, including the difficulty of managing high impact areas, concurrent skin and joint disease, and the aspirational goal of maintaining off-treatment remission, while emphasizing the importance of early and aggressive systemic intervention.